Status:
ACTIVE_NOT_RECRUITING
Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
Rhode Island Hospital
M.D. Anderson Cancer Center
Conditions:
Renal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to better understand how effective ablation is for destroying tumor cells in the kidney and whether quality of life is improved for patients. Participation in ARMOR may in...
Eligibility Criteria
Inclusion
- Retrospective enrollment:
- \- Patients having undergone percutaneous, open or laparoscopic energy ablation of a renal mass.
- Prospective enrollment:
- \- Patients scheduled to undergo, rather than having undergone, percutaneous, open or laparoscopic energy ablation of a renal mass.
Exclusion
- Patients not having undergone, or considered candidates for percutaneous, open or laparoscopic energy ablation of a renal mass
- Non-English speaking patients
- Patients under the age of 18.
Key Trial Info
Start Date :
June 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
294 Patients enrolled
Trial Details
Trial ID
NCT01888198
Start Date
June 1 2013
End Date
June 1 2026
Last Update
July 25 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles
Los Angeles, California, United States, 90095
2
University of Maryland Medical Center
Baltimore, Maryland, United States, 21201
3
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
4
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107